Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.

This study looked at how effective increasing the dose of eptinezumab is for patients with difficult-to-treat migraines. Researchers focused on adults who had high-frequency episodic or chronic migraines. These patients initially received 100 mg doses and showed only a partial response. Specifically, they had a 30% to less than 50% reduction in their monthly headache days. After two doses of 100 mg, the dose was increased to 300 mg for the next two cycles. The main goal was to see how many patients could achieve a 50% or more reduction in headache days. The study involved 57 patients, mostly women, with an average age of 48 years. After increasing the dose, 57.9% of patients achieved significant improvement after the first cycle. This percentage increased to 64.9% after the second cycle, indicating that higher doses can be beneficial for some patients. Clinical relevance: This study shows that increasing eptinezumab to 300 mg may significantly help patients with difficult-to-treat migraines who initially respond only partially to the lower dose.